Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Amylyx Pharmaceuticals, Inc. (AMLX) had Receiveable Turnover of 195.46 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$87.37M |
|
$-301.74M |
|
$124.63M |
|
$-37.26M |
|
$402.10M |
|
$-314.73M |
|
$12.60M |
|
$-302.14M |
|
$-302.14M |
|
$-301.74M |
|
$-301.74M |
|
$-301.74M |
|
$-301.74M |
|
$-314.73M |
|
$-323.68M |
|
68.14M |
|
68.14M |
|
$-4.43 |
|
$-4.43 |
|
| Balance Sheet Financials | |
$189.43M |
|
$0.96M |
|
$4.20M |
|
$193.63M |
|
$28.41M |
|
-- |
|
$0.46M |
|
$28.87M |
|
$164.76M |
|
$164.76M |
|
$164.76M |
|
68.63M |
|
| Cash Flow Statement Financials | |
$-167.65M |
|
$75.65M |
|
$0.35M |
|
$170.92M |
|
$78.84M |
|
$-92.08M |
|
$33.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.67 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-42.65% |
|
-360.22% |
|
-360.22% |
|
-370.47% |
|
-345.81% |
|
-345.36% |
|
$-204.01M |
|
-- |
|
-- |
|
-- |
|
0.45 |
|
-- |
|
|
Receiveable Turnover |
195.46 |
1.87 |
|
-183.14% |
|
-183.14% |
|
-155.83% |
|
-183.14% |
|
$2.40 |
|
$-2.99 |
|
$-2.46 |
|